申请人:Pfizer, Inc.
公开号:US04863948A1
公开(公告)日:1989-09-05
A series of novel alkanesulphonamidophenyl-N-alkyl-N-(heterocyclic-alkyl)alkylamine derivatives have been prepared, including their pharmaceutically acceptable salts, wherein the heterocyclic moiety is a 5- or 6-membered nitrogen-containing heterocyclic group which is attached to the adjacent carbon atom by a carbon or nitrogen atom and optionally contains a further heteroatom selected from oxygen and nitrogen, said nitrogen-containing heterocyclic group being either (i) substituted by a phenyl or benzyl group or (ii) fused at two adjacent carbon atoms to a benzene ring, with the resulting heterocyclic ring moiety also being optionally substituted. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrythmias. The most preferred member compound of the series is 2-hydroxy-2-(4-methanesulphonamidophenyl)-N-methyl-N-[2-(6-chloro-2H-isoin dolin-1-on-2-yl)ethyl]ethylamine. Methods for preparing all these compounds from known starting materials are provided.
已制备一系列新颖的烷磺胺基苯基-N-烷基-N-(杂环烷基)烷胺衍生物,包括它们的药用盐,其中杂环基是一个5-或6-成员的含氮杂环基团,通过碳或氮原子连接到相邻的碳原子,并且可选地包含氧和氮等进一步杂原子,所述含氮杂环基团可以是(i)被苯基或苄基取代或(ii)与苯环上的两个相邻碳原子融合,从而形成的杂环环基团也可以是可选地取代的。这些特定化合物在治疗中作为高效的抗心律失常药物具有重要作用,因此对于治疗各种心律失常具有价值。该系列中最优选的成员化合物是2-羟基-2-(4-甲烷磺胺基苯基)-N-甲基-N-[2-(6-氯-2H-异喹啉-1-酮-2-基)乙基]乙胺。提供了从已知起始材料制备所有这些化合物的方法。